Market Overview

Alexion Pharmaceuticals Buy-Rated By Deutsche Bank


On October 20th, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced positive data in a new indication for Soliris – aHUS, Deutsche Bank reports.

“This is a rare disease in which the body attacks its own kidney,” Deutsche Bank writes. “Soliris reduced the need for plasma therapy, but also improved/stabilized kidney fxn. Our deep-dive into aHUS (p23-54) suggests the final data in aHUS (on Nov. 19th/20th at the American Society of Nephrology in plasma resistant & early ‘12 for plasma sensitive patients) will be clinically meaningful.”

Deutsche Bank has initiated a Buy rating, adding, “Our YE11 target price of $79/share is based on a DCF analysis which assumes 100% approvability of Soliris in aHUS & 60% success in transplant. Downside risks include failure in aHUS, FDA rejection in aHUS, and poor Soliris sales.”

Alexion currently trades at $67.61.

Posted-In: Alexion Deutsche BankAnalyst Ratings


Related Articles (ALXN)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

ENTG Beats EPS Estimates; Citi Maintains Hold Rating

Perrigo Company Announces Dividend Increase to 7 Cents